The Lloyds share price is rising, but I’d buy these stocks instead
More on: Image: Lloyds Banking Group
Lloyds Bank(LSE: LLOY) had a hard 2020, to be sure. But the Lloyds share price has come a long way from its lowest point. It has doubled, in fact.
Why the Lloyds share price could underwhelm
There is much to like about Lloyds Bank as a company. It is one of the UK’s largest banks, with a long legacy. The bank has recovered from more than one downturn. It is profitable even at a time when interest rates are low and retail banking is its biggest income generating segment.
This small-cap stock is recovering fast and the directors expect growth ahead
More on:
There was good news from small-cap stock
Epwin(LSE: EPWN) today. In the full-year results report, the low-maintenance building products maker declared the restoration of shareholder dividends.
I’ve written about the stock several times over the past few years. And the main attractions have always been a cheapish valuation and a high dividend yield. But with the share price near 97p, the forward-looking yield for 2021 is as low as about 2.8%.
US$12.3 TRILLION out of thin air…
And if you click here we’ll show you something that could be key to unlocking 5G’s full potential.
US$12.3 TRILLION out of thin air…
And if you click here we’ll show you something that could be key to unlocking 5G’s full potential.
As such, I believe steel demand will grow rapidly over the next few years. As one of the largest steel producers in Europe, Evraz could be one way to play this theme.
That said, steel’s a highly volatile business, and the company may not be suitable for all investors due to the unpredictable nature of steel production. Despite these risks, I’d buy the stock from my portfolio of UK shares today.
On the same theme, I’d also acquire shares in
Would I buy the Deliveroo, Volex, and Futura Medical shares now?
More on:
Deliveroo, of course, had a well-publicised initial public offering (IPO).
Volex is in a promising sector, and
Futura Medical may be at an inflection point.
Now all three have released updates. I think this is a good time to take a closer look at their performance.
US$12.3 TRILLION out of thin air…
And if you click here we’ll show you something that could be key to unlocking 5G’s full potential.
Deliveroo expects growth slowdown
Deliveroo has delivered impressive growth in the past year, partly due to the lockdown. This continues into the first quarter of the year. Its orders have risen by 114% from the year before. Its gross transaction value (GTV), which is the total value paid by customers, net of discounts and discretionary tips, rose by 130%.
Elliott Management has built a large stake in GlaxoSmithKline
More on:
Financial Times, activist hedge fund Elliott Management has built a multibillion-pound stake in
GlaxoSmithKline(LSE:GSK). The news broke today, and the GlaxoSmithKline share price is up 4.3% at the time of writing. Given that the broader
FTSE 100 is up only 0.58%, and other large-cap pharma stock prices have budged only slightly, it’s reasonable to assume that Glaxo shareholders have taken the news well.
Activist hedge fund target
Elliott Management which is headed up by billionaire investor Paul Singer has a history of taking large stakes in companies that it feels are underperforming. It then uses its influence as a large shareholder to push the board to make changes that it thinks will increase shareholder value.